Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
Therapy resistance represents an unmet challenge in the treatment of medulloblastoma. Accordingly, the identification of targets that mark drug-resistant cell populations, or drive the proliferation of resistant cells, may improve treatment strategies. To address this, we undertook a targeted approa...
Main Authors: | Louisa Taylor, Philippa K. Wade, James E. C. Johnson, Macha Aldighieri, Sonia Morlando, Gianpiero Di Leva, Ian D. Kerr, Beth Coyle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/4/1086 |
Similar Items
-
Medulloblastoma – an overview
by: A. V. Ciurea, et al.
Published: (2010-09-01) -
Is adult medulloblastoma merely the counterpart of pediatric medulloblastoma?
by: Gabriel Chun-Hei Wong, et al.
Published: (2020-01-01) -
Secreted protein YB-1 and its prognostic significance
by: A. A. Stavrovskaya, et al.
Published: (2017-10-01) -
MEDULLOBLASTOMA – CLINICAL AND THERAPEUTICAL ASPECTS
by: Catalin Prazaru, et al.
Published: (2017-06-01) -
Extraneural metastases in medulloblastoma
by: V M F Muoio, et al.
Published: (2011-01-01)